HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement of schizophrenic patients treated with [des-Tyr1]-gamma-endorphin (DTgammaE).

Abstract
It was postulated from animal experiments that gamma-endorphin and, in particular, the nonopiate-like peptide [des-Tyr1]-gamma-endorphin (DTgammaE, beta-lipotropin [beta-LPH]62-77) have neurolepic-like activity. To test this, 14 patients with long-lasting, relapsing schizophrenic or schizoaffective psychosis resistant to conventional neuroleptics were treated with DTgammaE. An open design was used first for six patients (study 1) and a double-blind, crossover design for the other eight (study 2). In study 1, all neuroleptic medication was discontinued and 1 mg of DTgammaE zinc phosphate was given daily intramuscularly for about seven days. In study 2, six patients were maintained with neuroleptic therapy and two patients were drug free; all eight received daily intramuscular injections of 1 mg of nonlasting DTgammaE in saline and solution for eight days. There was transient or semipermanent improvement in both studies in which the psychotic symptoms diminished or even disappeared. In study 2, there was a slight but significant improvement with the first treatment. Improvement continued and by day 4, the psychotic symptoms had almost disappeared. No toxic side effects were noted. These effects of DTgammaE may be a consequence of the normalization of beta-endorphin homeostasis in the brain.
AuthorsW M Verhoeven, H M van Praag, J M van Ree, D de Wied
JournalArchives of general psychiatry (Arch Gen Psychiatry) Vol. 36 Issue 3 Pg. 294-8 (Mar 1979) ISSN: 0003-990X [Print] United States
PMID369471 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Endorphins
  • Peptide Fragments
  • gamma-endorphin, des-Tyr(1)-
Topics
  • Adult
  • Aggression (drug effects)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Endorphins (therapeutic use)
  • Female
  • Hallucinations (drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Motor Activity (drug effects)
  • Peptide Fragments (therapeutic use)
  • Schizophrenia (drug therapy)
  • Schizophrenia, Catatonic (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: